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Abstract
Background: Gliomas are the most common primary brain tumor in both children and adults. The prognosis for
glioblastoma (GBM), the most common type of malignant glioma, has remained dismal, with median survival a little
over one year despite maximal therapy with surgery, chemotherapy, and radiation. Although immunotherapy has
become increasingly successful against many systemic tumors, clinical efficacy against brain tumors has been
limited. One reason for this is an incomplete understanding of the local immunologic tumor microenvironment,
particularly the function of large numbers of infiltrating myeloid derived cells. Monocytes/microglia are myeloid
derived immunomodulatory cells, and they represent the predominant infiltrating immune cell population in gliomas.
Our group has previously demonstrated using complementary in vitro and in vivo approaches that GBM tumor cells
polarize tumor-associated myeloid cells (TAMs) and suppress their immunostimulatory function.
Methods and Results: To better understand the mechanisms responsible for this immunosuppression, we used
gene expression profiling of stimulated monocytes in the presence or absence of GBM tumor cells. Our analysis
identified caveolin-1 (CAV1), a plasma membrane molecule with pleiotropic functions, as significantly up-regulated in
monocytes in the presence of GBMs. We validated these findings ex vivo by confirming up-regulation of CAV1 in
TAMs isolated from GBMs immediately after surgical resection. Finally, we demonstrate that siRNA inhibition of
CAV1 restores myeloid cell function, as measured by TNF-alpha secretion, in the presence of GBMs.
Conclusions: Restoration of TAM function through pharmacologic blockage of CAV1 may facilitate more successful
immunotherapeutic strategies directed against a variety of solid human tumors infiltrated by TAMs.
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Introduction
Currently, the majority of research involving the immunology
of malignant gliomas focuses on T cells. This is in part because
there is clear evidence that T cells infiltrate glioblastomas
(GBMs) [1-5] and also because of increasing success with
dendritic cell-based vaccinations to boost cytotoxic T cell
responses (reviewed in 6). However, there is increasing
awareness that myeloid derived immune cells play a significant
role in the local tumor microenvironment. In both animal
models and cancer patients, for example, myeloid-derived
suppressor cells have been implicated in the generation and
propagation of local tumor immunosuppression [7]. In the
central nervous system, until recently [8,9] the contribution of
myeloid cells in the regulation of the local immune response to
GBMs has largely been overlooked.
Our group and others have reported that tumor associated
myeloid cells (TAMs) greatly outnumber any other immune cell
type in human gliomas including T cells [8-13]. We recently
demonstrated that GBM tumor cells inhibit the ability of myeloid
cells to respond to a wide array of potent stimuli in vitro, and
moreover, can render them tolerogenic [14]. To determine if
our observations regarding the frequency and functional
impairment of myeloid cells in human GBMs were also present
in vivo, we developed a novel animal model by injecting PDGF-
driven murine glioma cells into the white matter of mice [15].
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e77397
Similar to both our findings in vitro and from human GBMs ex
vivo, TAMs from our murine model were found at high
frequency but with significant functional impairment [11].
To determine if a single, dominant molecule was responsible
for the GBM-mediated suppression of TAM function, we
performed a comprehensive, array-based approach to identify
pathways and mechanisms by which GBMs suppress myeloid
cell activation. Our results identified caveolin-1 (CAV1) as
significantly up-regulated in myeloid cells in the presence of
GBM tumor cells. We then validated this finding ex vivo by
confirming upregulation of CAV1 in TAMs isolated from GBMs
immediately after surgical resection. Finally, we demonstrated
that blocking CAV1 with siRNA inhibition restored myeloid cell
function, as measured by TNF-alpha secretion, in the presence
of GBMs.
Materials and Methods
Monocyte and PBMC extraction
Peripheral blood mononuclear cells (PBMC) were isolated
from freshly isolated blood from healthy subjects. Under
approval from the Columbia University Institutional Review
Board (IRB) (protocol IRB-AAAA4666), blood samples and
brain tumor specimens are collected from patients by a broker
and deposited in an institutional tumor bank. Specimens are
provided to Columbia University personnel upon request after
complete de-identification. As per the above protocol, further
research with these de-identified specimens is classified as
NOT human-related research and no further IRB approval is
required. Healthy subjects were used to obtain normal
peripheral blood monocytes for use in these studies. The first
group was used for the microarray study and consisted of both
men (n = 4) and women (n = 4) with a mean age of 44 years. A
separate group of healthy subjects was used to confirm the
microarray data and consisted of both men (n = 3) and women
(n = 2) with a mean age of 41 years. Blood was drawn into
vacutainers containing lithium-heparin anti-coagulant (BD
Biosciences). PBMCs were extracted using Ficoll density
gradient centrifugation. Monocytes were then isolated from
PBMCs by negative selection using immunomagnetic beads
(Miltenyi Biotec, Auburn, CA).
Co-culture assays and re-sorting of monocytes
following co-culture
Ex vivo monocytes (2x106 cells/well) were cultured alone or
with a primary GBM tumor cell line (RCA; obtained by culture
and expansion of an ex vivo tumor specimen in cell culture
medium [14]) at a ratio of 2:1 monocytes:GBM in polystyrene
2.5 ml tubes in the absence or presence of lipopolysaccharide
(LPS; 1ug/ml). After 4 hours of co-culturing in endotoxin free
conditions, monocytes were stained with CD11b-PE
monoclonal mouse anti-human antibody (BD Pharmingen, San
Diego, CA) and a FACSAria (Becton Dickinson, San Diego,
CA) cell sorter was used to isolate monocytes (CD11b+) to
obtain a highly purified cell population (>99% purity). Adult
normal human astrocytes were purchased from two
commercial sources (Cambrex/Lonza; All Cells) and cultured in
Astrocytes Basal Media supplemented with astrocyte growth
medium SingleQuots (Lonza) [14].
Gene expression analysis
Applied Biosystems Human Genome Survey Arrays V2.0
were used to determine the transcriptional profiles of 26
samples. DIG-UTP labeled cRNA was generated and linearly
amplified from 500 ng total RNA using the Chemiluminescent
RT-IVT Labeling Kit v 2.0 (Applied Biosystems, Foster City,
CA, US) as described by the protocol. Array hybridization,
chemiluminescence detection, image acquisition and analysis
were performed using Applied Biosystems Chemiluminescence
Detection Kit and Applied Biosystems 1700
Chemiluminescence Microarray Analyzer following the
manufacturer’s instructions. Each microarray was pre-
hybridized at 55°C for 1hr in hybridization buffer with blocking
reagent. Between 4 and 20 ug DIG-labeled cRNA targets were
first fragmented, mixed with internal control target and
hybridized to the prehybridized microarrays in a volume of
1.5ml at 55°C for 16 hrs. After hybridization, the arrays were
washed with hybridization wash buffer and chemiluminescence
rinse buffer. Enhanced chemiluminescent signals were
generated by incubating arrays with Alkaline Phosphatase
conjugated anti-digoxigenin antibody followed by incubation
with Chemiluminescence Enhancing Solution and a final
addition of Chemiluminescence Substrate. Four images were
collected for each microarray using the ABI 1700
Chemiluminescent Microarray Analyzer. Images were auto-
gridded and the chemiluminescent signals were quantified,
corrected for background and spot and spatially normalized.
Statistical analysis
The entire statistical analysis was performed within "R"
software environment (www.r-project.org). The ABarray
package (Yongming Andrew Sun, Applied Biosystems) from
Bioconductor (www.bioconductor.org) was used for quality
control purposes and quantile normalization. 14414 genes
showed reliable expression values throughout all comparisons
based on standard filter criteria of the ABarray package. One
sample had to be omitted from further analysis because of low
number of probes detectable and low detection concordance.
The Pairwise Local Pooled Error Test (PLPE package from
Bioconductor) was performed in order to compare gene
expression values of unstimulated monocytes against
monocytes stimulated with LPS (1), stimulated monocytes
against stimulated monocytes cocultured with glioblastoma
cells (2) and stimulated monocytes cocultured with
glioblastoma cells against stimulated monocytes cocultured
with human astrocytes (3). Genes were filtered by FDR < 0.001
of the Paired L-statistic or Paired Lw-statistic for the second
comparison and FDR < 0.01 of the third comparison. The
majority of these genes were not affected by LPS stimulation
(FDR > 0.01 in first comparison).
Collection of human tumors and processing of ex vivo
specimens
Fresh human tumor and normal brain specimens were
obtained according to institutional review board guidelines (see
Restoration of Myeloid Function in Glioblastoma
PLOS ONE | www.plosone.org 2 October 2013 | Volume 8 | Issue 10 | e77397
above). Normal brain specimens were isolated from the
anterior temporal tip in patients undergoing non-tumor temporal
lobe epilepsy surgery. All tumor specimens were classified by
neuropathogists as WHO grade IV glioblastomas. Nine patients
had classical type GBM and one had GBM with
oligodendroglial components. After specimens were collected
in the operating room, they were transported and mechanically
dissociated on ice in serum-free medium (modified Eagle’s
medium containing 20nmol/L 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid) and enzymatically digested using
DNase (100ug/mL; Sigma Chemical Co., St. Louis, MO) and
trypsin for 20 minutes. Single-cell suspensions were obtained
by passing tumor slurries through a 100-um filter. Tumor cells
were purified by density centrifugation using 30% sucrose
solution for 20 minutes at 4500 rpm. The cells were washed in
PBS twice and used for cell sorting.
Cell sorting
Cell sorting was performed to obtain purified TAM
populations from single-cell suspensions from ex vivo
specimens. Cells were placed in PBS with 2% fetal bovine
serum and allowed to incubate with anti-CD11c-PE antibody
and anti-CD11b-APC antibody for 20 minutes at room
temperature. Cells were washed, resuspended in PBM
containing 2% fetal bovine serum with 1:1000 dilution of 4’,6-
diamidino-2-phenylindole (DAPI; Dako, Fort Collins, CO). Cells
were distinguished from debris and dead cells on the basis of
appropriate scatter properties. Cells included in the range of
DAPI-, CD11b+, and CD11c+ were collected as the TAM
population [16] and used for mRNA analysis.
siRNA transfection
siRNA transfection was performed to knock down each
candidate gene in a monocyte cell line (THP-1 cells [Public
Health England]). 24 hours before transfection, THP-1 cells
were plated in 6-well plate at 5 x 105 per well in RPMI1640
containing 10% FBS and PMA (10-8M) with no antibiotics.
Transfection was done with Lipofectamine RNAiMAX
(Invitrogen) with siRNA at a final concentration of 10nM
according to the manufacturer’s recommendation. After 24hr-
incubation, all cells were detached by trypsin and collected and
used for coculture experiments. Some of the cells were used
for extracting RNA for mRNA analysis of each candidate gene.
All siRNAs were synthesized by Ambion (Darmstadt, Germany)
and were purchased as annealed RNA-duplexes.
mRNA expression analysis
mRNA expression analysis was done for ex vivo sorted TAM
samples and THP-1 cells transfected with siRNA. Total RNA
from the samples was obtained using an RNeasy Mini Kit
(Qiagen) following the manufacturer’s instructions. Synthesis of
cDNA was carried out using Oligo(dt) primers and Superscript-
II reverse transcriptase according to the manufacturer’s
specifications (Invitrogen). Real-time PCR was performed in
duplicate reactions employing ABI PRISM 7300 (Applied
Biosystems, Darmstadt, Germany) with standard conditions.
RNA levels reported are relative to GAPDH, normalized using
the equation 1/2ΔCt. All primers and probes were purchased
from Applied Biosystems.
Coculture assays
THP-1 (1 X 105) cells transfected with siRNA were cultured
alone or with 1 X 105 tumor cells from a primary GBM cell line
[14][17]) in duplicate in round-bottom 96-well plate in RPMI
1640 supplemented with 10% FBS. LPS was added at 1ug/ml
as a stimulus. After 24-hr incubation, all supernatants were




Human monocytes from eight healthy donors were freshly
isolated and left unstimulated or stimulated with LPS under
three different conditions: alone or in the presence of GBM
tumor cells or normal human astrocytes (Figure 1a). Unlike
many other GBM microarray studies, we next re-isolated
monocytes using Fluorescence-activated Cell Sorting (FACS)
based on forward scatter (FSC) and side scatter (SSC)
properties that were distinct from the GBM or astrocytes. We
then confirmed purity in small samples based on CD11b
expression. This served to avoid contamination by GBM and
other cells prior to processing for RNA extraction and
microarray analysis (Figure 1b). Using a human genome
survey microarray platform, we employed 32,878 probes for the
interrogation of 29,362 human genes, of which 14,414 genes
could be analyzed because they passed all quality control
criteria (Figure 2). Among these genes, 846 were affected by
LPS stimulation, while the vast majority (13,548) were
unaffected by LPS stimulation. Among these subsets of genes,
we then identified genes that were differentially affected by co-
culturing in the presence of a GBM tumor cell line, relative to
stimulation by LPS alone. Among genes up-regulated by LPS
stimulation, the majority were down-regulated in co-culture with
GBM tumor cells. In contrast, co-culture with GBM tumor cells
predominantly up-regulated genes among the subset that was
unaffected by LPS stimulation. Finally, among genes affected
by co-culture with the GBM tumor cell line and affected (136
genes) or unaffected by LPS stimulation (164 genes), we
further identified those genes that were unaffected by co-
culture with non-transformed, primary human astrocytes,
resulting in two final subsets of 33 genes and 26 genes.
Review of the literature suggested an interesting candidate
gene from each of the two final gene subsets based on their
suggested roles in regulation of inflammation. Up-regulation of
both AXL [18] and Caveolin-1 (CAV1) [19] has been
demonstrated to reduce inflammation via inhibition of TNF-
alpha production and were therefore investigated further. We
confirmed up-regulation of these two molecules in an
independent data set using freshly isolated monocytes from
healthy donors (n=5). There was significant up-regulation of
CAV1 and AXL when monocytes were stimulated with LPS in
the presence of GBMs compared to stimulated monocytes
alone as measured by quantitative PCR. The expression
changes of CAV1 and AXL in monocytes in the presence of
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Figure 1.  Experimental design and sample processing for microarray analysis of GBM-induced molecules in co-cultured
myeloid cells.  (a) ABI1700 cDNA microarrays were used to analyze global changes in gene transcripts using a cutoff in the
change of gene expression of > 2 fold. We analyzed the expression profile of 29,362 human genes using RNA samples from
unstimulated monocytes (n=8), LPS-stimulated monocytes (n=8), LPS-stimulated monocytes cocultured with glioblastoma cells
(n=8), and monocytes cocultured with human astrocytes (n=2). Of these, 14,414 gene expression profiles were used for subsequent
analysis, as this set of genes passed all quality control criteria. Local Pooled Error Tests (PLPE package from Bioconductor) were
performed comparing gene expression values of monocytes stimulated with LPS in the absence vs. presence of GBM cells and
subsequently stimulated monocytes co-cultured with GBM cells vs. stimulated monocytes co-cultured with primary human
astrocytes. (b) After 4 hours of culture in 4 experimental conditions, monocytes were isolated from GBM or human astrocytes based
on FSC/SSC properties. Purity was re-confirmed in a small fraction of each sample based on CD11b expression.
doi: 10.1371/journal.pone.0077397.g001
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GBM were 43.6 and 5.3 fold (P=0.02, 0.04), respectively,
compared to stimulated monocytes in the absence of GBM
tumor cells.
Ex vivo analysis of tumor associated myeloid cells
Multiple lines of evidence both in vitro and in murine models
point to the local tumor microenvironment as the major site
where most immune modulation involving the myeloid
compartment stem from [20]. However, comparable data in
GBM patients are not well known. We therefore examined
TAMs directly ex vivo from patients harboring primary GBMs
(n=10) and normal brain (n=3). Immediately after surgical
resection, fresh specimens were manually minced and reduced
to single cell suspensions as previously described [12,17].
TAMs were isolated using FACS (CD11b+/CD11c+) (Figure
3a), followed by RNA extraction, cDNA preparation and rtPCR
amplification. Gene expression analysis demonstrated a
statistically significant up-regulation of CAV1 in TAMs from
patients with GBMs (6.32 fold) compared to normal brain (p=
Figure 2.  Flow schematic summarizing results of GBM-induced genes in co-cultured human myeloid cells.  The number of
genes satisfying each selection criteria are summarized, resulting in two gene subsets: those affected by LPS stimulation as well as
culture with GBM tumor cells but not non-transformed human astrocytes, exemplified by AXL, and those unaffected by LPS
stimulation but affected by GBM tumor cells, exemplified by CAV1. Additional genes within these two gene susbsets included
CDCP1, CKS2, STC1, KRT18, and PHLDA2, but their differential expression could not be independently replicated (data not
shown).
doi: 10.1371/journal.pone.0077397.g002
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0.03). AXL expression was also up-regulated ex vivo in TAMs
from patients with GBMs (2.46 fold) compared to normal brain,
but did not reach statistical significance (p = 0.1) (Figure 3b).
Figure 3.  Ex vivo isolation and expression of AXL and
CAV1 among myeloid cells in non-inflamed human CNS
tissue and GBMs.  (a) GBM tumor specimens or non-inflamed
CNS tissue isolated from the anterior temporal tip during
epileptic surgery were processed to single cell suspensions
and stained with antibodies against CD11b and CD11c to sort
infiltrating monocytes/microglia. (b) Quantitative PCR analysis
of expression levels of AXL and CAV1 were determined for
monocytes/microglia from ex vivo non-inflamed human CNS
tissue (n=3) and primary GBMs (n=10).
doi: 10.1371/journal.pone.0077397.g003
Inhibition of CAV1 restores myeloid cell function as
measured by TNF-α secretion
Our ex vivo analysis of TAMs validated up-regulation of
CAV1 and to a lesser extent AXL in the local tumor
microenvironment, but the functional significance of these
findings was unclear. To determine whether these genes
contributed to the GBM-mediated suppression of myeloid cells,
we used siRNA inhibition to block CAV1 and AXL expression in
our co-culture model. PMA stimulated monocytes were first
transfected with siRNA specific for CAV1 or AXL, nonspecific
siRNA, or left untransfected. siRNA transfection consistently
reduced CAV1 and AXL gene expression by between 60-75%
(data not shown). After 24 hours of co-culture in the presence
or absence of GBM cells, supernatants were collected and
TNF-alpha secretion was measured by ELISA as previously
described [11,14]. Consistent with our previous data, there was
a significant reduction in TNF-alpha secretion in LPS
stimulated monocytes cultured in the presence of GBM tumor
cells and transfected with nonsense siRNA (161pg/ml)
compared to LPS stimulated monocytes in the absence of
GBM tumor cells (414 pg/ml) (Figure 4a). When siRNA specific
for CAV1 was transfected in co-cultures of moncytes stimulated
with LPS in the presence of GBM tumor cells, however, TNF
alpha secretion increased by approximately 50% (315 pg/ml vs
161 pg/ml). Results obtained in four independent experiments
demonstrated that transfection of monocytes with anti-CAV1
siRNA restored 42-78% of monocyte activity as measured by
TNF-alpha secretion compared to transfection with non-specific
siRNA (p=0.0278)(Figure 4b). Importantly, transfection with
siRNA specific for AXL did not reduce the GBM-mediated
immunosuppression and restore TNF-alpha secretion, further
supporting the specificity of CAV1 up-regulation to the
observed myeloid cell suppression conferred by GBM tumor
cells.
CAV1 was initially described as a member of a family of
scaffolding proteins that interacts with signaling molecules and
regulates their activity [19]. It has been reported to have many
functions, including the formation of caveolae, membrane
trafficking, signal transduction pathways, apoptosis, calcium
and lipid homeostasis in fibroblasts, adipocytes, and
endothelial cells [21]. More recent evidence indicates that
CAV1 also suppresses inflammation [22]. CAV1 expression
has been demonstrated in multiple immune cells including
monocytes/macrophages, dendritic cells, and lymphocytes
[23,24]. Similar to our findings in human GBMs, upregulation of
CAV1 in murine macrophages dramatically reduced pro-
inflammatory cytokine production (TNF-alpha and IL-6) and
increased anti-inflammatory cytokine production (IL-10) [19].
Reported mechanisms of CAV1 mediated immunosuppression
in murine models include inhibition of eNOS activity [25] and
activation of the MKK3/p38 pathway [19].
Taken together, these data indicate that GBM-mediated
suppression of tumor-associated myeloid cell function is
mediated at least in part by CAV1, and importantly, that activity
can be restored by suppressing CAV1. Currently FDA
approved pharmacological inhibitors of CAV1 such as
lovastatin and celecoxib [26] may be useful in altering the local
tumor microenvironment and augmenting current
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immunotherapy against human glioblastoma and a variety of
other solid human tumors characterized by the presence of
large numbers of TAMs.
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